213.1 ð é«åžçç
213.1.0.1 ð äžé éé»
- Virus: dsDNA Hepadnaviridae; partially double-stranded circular DNA
- Surface antigen (HBsAg) + core antigen (HBcAg) + e antigen (HBeAg)
- Transmission:
- Vertical (perinatal â primary in endemic regions)
- Sexual (high-risk in adolescents/adults)
- Blood (transfusion, IDU, healthcare exposures)
- Horizontal household (rare with hygiene)
- Global Burden: 296M chronic carriers; 887K deaths/yr from HBV (cirrhosis + HCC)
- High prevalence regions: sub-Saharan Africa, E + SE Asia (Taiwan, Korea, Vietnam)
- Pediatric infection â 90% chronic; adult acquisition â 95% clear (only 5% chronic)
- Phases of Chronic HBV (AASLD 2018):
- Immune tolerant (HBeAg+, high viral load, ALT normal)
- Immune active (HBeAg+) (high viral load, ALT elevated)
- Inactive carrier (HBeAg-, low viral load, ALT normal)
- Immune reactivation (HBeAg-) (variable viral load, ALT elevated, mutations)
- Diseases:
- Acute hepatitis (mild to fulminant; chronic in pediatric > adult)
- Chronic hepatitis with progression to cirrhosis + HCC
- HBV reactivation with immunosuppression (anti-CD20 like rituximab, chemo, transplant)
- Extrahepatic manifestations: glomerulonephritis (membranous), PAN (polyarteritis nodosa)
- Diagnosis:
- HBsAg â current infection (acute or chronic)
- Anti-HBs â recovery or vaccination immunity
- HBeAg / anti-HBe â replication marker
- HBV DNA quantitative â viral load
- Anti-HBc IgM â acute infection; IgG = chronic or past
- Treatment:
- Tenofovir alafenamide (TAF) â preferred (less renal/bone toxic than TDF)
- Tenofovir disoproxil fumarate (TDF) â alternative
- Entecavir â first-line oral (no NTC + nucleoside-naive)
- Peg-interferon-α â limited use now (chronic HBeAg+ select)
- Lifelong typically for chronic HBV (cure rare)
- Cure Paradigm (2024-2025): novel therapeutics under trial:
- Bulevirtide (Hepcludex) â NTCP receptor inhibitor (also for HDV)
- GalNAc-siRNA (Vir-2218, etc.) â silences HBsAg
- Capsid assembly modulators (e.g., vebicorvir)
- Therapeutic vaccines + immune modulators
- Goal: functional cure (HBsAg loss + †1000 IU/mL HBV DNA off-treatment)
- Vaccine: recombinant HBsAg; universal childhood + at-birth doses; 3-dose series; > 95% protection
- Prevention: birth-dose vaccine + HBIG + universal childhood vaccination + sexual safety
213.1.0.2 1ïžâ£ Virology
213.1.0.2.1 Structure
- 42 nm Dane particle (complete infectious virion)
- Outer envelope: HBsAg
- Inner core: HBcAg + viral DNA + DNA polymerase
213.1.0.2.2 Genome
- Partially dsDNA, ~ 3.2 kb (smallest mammalian DNA virus)
- 4 overlapping ORFs: S (surface), C (core/precore), P (polymerase), X (X protein â transactivator)
- Polymerase = reverse transcriptase (replication via RNA intermediate, unusual for DNA virus)
213.1.0.2.3 Replication Cycle
- Hepatocyte binding via NTCP receptor (sodium-taurocholate cotransporting polypeptide)
- Nuclear import + conversion to cccDNA (covalently closed circular DNA) â major obstacle to cure (persists nuclear, transcription template)
- Pre-genomic RNA â encapsidation â reverse transcription â new virions
- Integration into host genome possible (oncogenic potential â HCC)
213.1.0.2.4 Genotypes
- A, B, C, D, E, F, G, H, I, J
- Taiwan + Asia: B, C predominant (C associated with worse HCC outcome)
- Affects treatment response in some scenarios
213.1.0.2.5 Mutations
- Precore mutations (G1896A): no HBeAg production but still replicating (âHBeAg-negative chronic hepatitisâ)
- Basal core promoter mutations (T1762/A1764): reduced HBeAg, increased HCC risk
- Surface escape mutations: vaccine breakthrough rare
- YMDD motif mutations: lamivudine resistance (historical)
- rtN236T: adefovir resistance
- Entecavir + tenofovir resistance very rare
213.1.0.3 2ïžâ£ Epidemiology
213.1.0.3.1 Global Distribution
- 296M chronic HBV globally (2024 WHO)
- 887K HBV-related deaths/yr (cirrhosis + HCC)
- High prevalence:
- Sub-Saharan Africa (5-10% HBsAg+)
- E + SE Asia (5-10%; China, Taiwan, Korea, Vietnam, Cambodia)
- Indigenous populations (Alaskan, Aboriginal)
- Intermediate (2-5%): Eastern Europe, Middle East
- Low (< 2%): Western Europe, USA, Australia, Japan (rising due immigration)
213.1.0.3.2 Transmission
- Vertical (perinatal):
- Major route in endemic regions
- Mother HBsAg+ + HBeAg+ â ~ 90% transmission without intervention
- With birth-dose vaccine + HBIG â < 5% transmission
- Sexual: high-risk adolescents + adults
- Blood: transfusion (very rare now with screening); IDU; healthcare needlestick
- Horizontal household contact: shared toothbrush, razor; rare with good hygiene
- Tattoo, piercing, acupuncture: poorly sterilized equipment
213.1.0.4 3ïžâ£ Clinical
213.1.0.4.1 Acute HBV
- 1-6 months incubation
- 70% subclinical or mild
- 30% symptomatic acute hepatitis:
- Prodrome 1-2 wk: malaise, anorexia, nausea, fatigue
- Icterus 2-4 wk: jaundice, hepatomegaly
- Resolution 1-3 months
- Fulminant hepatic failure: 1% adults (severe; transplant)
- Adults: 95% clear; pediatric: 90% chronic
213.1.0.4.2 Chronic HBV (⥠6 months HBsAg+)
213.1.0.4.2.1 Immune Tolerant Phase
- Young, perinatally infected
- HBeAg+, HBV DNA very high (10^7+ IU/mL)
- ALT normal
- No significant liver disease activity
- May persist decades
213.1.0.4.2.2 Immune Active Phase (HBeAg+)
- ALT elevated (immune-mediated hepatocyte damage)
- HBV DNA still high
- Liver biopsy: inflammation + fibrosis
- Progressive without treatment
213.1.0.4.2.3 Inactive Carrier Phase
- HBeAg seroconversion to anti-HBe
- HBV DNA low (< 2,000 IU/mL)
- ALT normal
- Best prognosis but still risk of reactivation
213.1.0.4.2.4 Immune Reactivation / HBeAg-Negative Chronic Hepatitis
- Often precore/BCP mutations
- HBeAg negative, anti-HBe positive
- HBV DNA elevated (fluctuating)
- ALT elevated
- Progressive disease
213.1.0.4.2.5 Cirrhosis + HCC
- 20-30% of chronic HBV develop cirrhosis
- HCC risk 100-200Ã general population
- Even non-cirrhotic chronic HBV has HCC risk (integration + X protein effects)
- Surveillance: liver US + AFP q6 mo in cirrhotic, high-risk Asian
213.1.0.4.2.6 HBV Reactivation
- Major concern with immunosuppression:
- Anti-CD20 (rituximab, ocrelizumab) â highest risk
- High-dose steroids (⥠20 mg prednisone à 4+ wk)
- Chemotherapy
- Anti-TNF
- Solid organ + HSCT
- Anti-CD52 (alemtuzumab)
- Risk highest in HBsAg+ patients; even anti-HBc-only + HBsAg-negative patients can reactivate (occult HBV)
- Mortality 30%+ if reactivation
- Prophylaxis with TDF/TAF or entecavir in high-risk groups
- AASLD recommendations for HBV screening before immunosuppression
213.1.0.5 4ïžâ£ Diagnosis
213.1.0.5.1 Serologic Markers
| Marker | Significance |
|---|---|
| HBsAg | Current infection (acute or chronic) |
| Anti-HBs | Immunity (vaccination or natural recovery) |
| HBeAg | Active replication (high infectivity) |
| Anti-HBe | Lower replication (better prognosis) |
| Anti-HBc IgM | Acute infection |
| Anti-HBc IgG | Past or chronic infection |
| HBV DNA quantitative | Viral load (treatment monitoring) |
213.1.0.5.2 Common Interpretation Patterns
| HBsAg | Anti-HBs | Anti-HBc | Pattern |
|---|---|---|---|
| + | - | + IgM | Acute HBV |
| + | - | + IgG | Chronic HBV |
| - | + | + IgG | Past infection, immune |
| - | + | - | Vaccine immunity |
| - | - | + IgG isolated | Past infection + low titer; or occult HBV |
| - | - | - | Susceptible |
213.1.0.5.3 Liver Assessment
- ALT/AST levels (varies by phase)
- Bilirubin, albumin, INR
- Platelets (cirrhosis indicator)
- Liver biopsy (historical); now largely replaced by:
- FibroScan (transient elastography) â non-invasive fibrosis
- APRI + FIB-4 scores
- Liver imaging (US + Doppler) for cirrhosis + HCC surveillance
213.1.0.6 5ïžâ£ Treatment
213.1.0.6.2 First-Line Drugs
213.1.0.6.2.1 Tenofovir Alafenamide (TAF)
- 25 mg PO qd
- Preferred (less renal + bone toxicity than TDF)
- No resistance documented
- Pregnancy: limited data but approved
213.1.0.6.2.2 Tenofovir Disoproxil Fumarate (TDF)
- 300 mg PO qd
- Standard since 2008
- Renal + bone toxicity over years
- Pregnancy: well-studied, safe
- No clinical resistance
213.1.0.6.2.3 Entecavir
- 0.5 mg PO qd (1 mg if prior lamivudine R)
- First-line oral
- Resistance rare in nucleoside-naive
- Should not be used if lamivudine resistance (higher entecavir R risk)
213.1.0.6.2.4 Lamivudine (Older)
- High resistance rate (~ 80% over 4 yr)
- No longer first-line
- Pregnancy historical
- Cheap; still used in resource-limited
213.1.0.6.2.6 Peg-Interferon-α-2a
- 180 µg SC weekly à 48 wk
- Limited use: select HBeAg+ chronic hepatitis (younger, no cirrhosis, low HBV DNA, favorable genotype)
- 30% seroconversion to anti-HBe
- 5-10% HBsAg loss long-term
- Side effects: flu-like, depression, cytopenia, autoimmune flare
- Not for cirrhosis (decompensation risk)
213.1.0.6.3 Treatment Duration
- Lifelong typically (suppression, not cure)
- Stop criteria limited:
- HBeAg seroconversion + sustained HBeAg negative (after 12+ mo continued)
- HBsAg loss (rare, ~ 5% over years)
- Older patients with low risk (case-by-case)
- Donât stop in cirrhosis (decompensation + HCC risk)
213.1.0.6.4 Vertical Prevention
- Tenofovir 3rd trimester if maternal HBV DNA > 200,000 IU/mL
- Birth-dose vaccine within 12 hours of delivery
- HBIG if mother HBsAg+
- With combination: < 5% vertical transmission
213.1.0.6.5 HBV/HDV Co-Infection
- HDV requires HBsAg for entry
- Treatment: see Ch 215 (bulevirtide, peg-IFN)
213.1.0.6.6 HBV/HIV Co-Infection
- HBV-active ART agent included (TDF/TAF + emtricitabine)
- Single regimen treats both
213.1.0.6.7 HCC Treatment
- Surveillance + early detection critical
- Curative: resection, transplant, ablation, transarterial chemoembolization
- Advanced: sorafenib, lenvatinib, regorafenib, atezolizumab+bevacizumab, immune checkpoint inhibitors
- TACE, Y-90 radioembolization for intermediate stage
213.1.0.6.8 HBV Cure Paradigm (2024-2025)
213.1.0.6.8.1 Goals
- Functional cure: HBsAg loss + sustained suppression
- Sterilizing cure (full cccDNA elimination): aspirational
213.1.0.6.8.2 Investigational Therapeutics
- Bulevirtide (Hepcludex) â NTCP receptor inhibitor; HDV approved EU 2020; HBV ongoing trials
- GalNAc-siRNA: VIR-2218 (Vir Biotechnology), bepirovirsen (GSK), ARC-520
- Silences HBsAg expression via RNA interference
- Combination with antiviral + immune modulator
- Capsid assembly modulators: vebicorvir, JNJ-6379
- Prevent capsid formation + viral assembly
- Core protein inhibitors: alternative mechanism
- Therapeutic vaccines: GS-4774, HepTcell â restore immune response
- PD-1 inhibitors + checkpoint inhibitors: revive exhausted T cells
- CRISPR + antisense oligonucleotides: research level
- REEF-1 study: combination GalNAc-siRNA + bepirovirsen for sustained HBsAg loss
213.1.0.7 6ïžâ£ Prevention
213.1.0.7.1 Vaccine
- Recombinant HBsAg (yeast-produced, no infectious component)
- 3-dose series: 0, 1, 6 months (some 2-dose alternatives â Heplisav-B 2 doses 1 mo apart)
- > 95% efficacy seroconversion in healthy
- Pregnancy: safe + recommended if at-risk
213.1.0.7.2 Recommendations (ACIP 2024)
- Universal childhood vaccination + birth dose within 12 hr
- Adults 19-59: universal vaccination 2022 update
- Adults 60+ with risk factors: indicated
- Higher-risk groups regardless of age:
- Sexual partners of HBsAg+
- MSM, multi-partner
- IDU
- Healthcare workers
- HIV+, immunocompromise
- Travelers to endemic regions
- Hemodialysis
- Chronic liver disease
213.1.0.7.3 Birth-Dose Vaccine
- Within 12 hours of birth for all infants (WHO recommendation; many countries)
- Plus HBIG within 12 hr if mother HBsAg+
- 3-dose vaccination series completion
- Reduces vertical transmission > 95%
213.1.0.7.4 HBIG (Hepatitis B Immunoglobulin)
- Passive antibody
- Used:
- Newborns of HBsAg+ mothers (with birth-dose vaccine)
- Post-exposure prophylaxis for unvaccinated or non-responder healthcare workers
- Liver transplant for HBV+ recipients (to prevent recurrence)